Skip to content

Earnings yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.9%+1.6pp
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
3.8%
Gilead Sciences logo
Gilead SciencesGILD
5.3%+1.1pp
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-12.5%-0.7pp
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-25.7%-6.8pp
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-26.1%-10.1pp

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total debt$75.3M-17.5%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$912.8M+54.1%
Enterprise value$904.32M+53.9%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×
Current ratio1.3×-2.1×

Where this comes from

Calculated from Sana Biotechnology’s reported figures.

Based on trailing twelve months.

The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sana Biotechnology's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sana Biotechnology's earnings yield?
Sana Biotechnology (SANA) reported earnings yield of -31.5% in Q1 2026.
How has Sana Biotechnology's earnings yield changed year-over-year?
Sana Biotechnology's earnings yield increased by 43.0% year-over-year, from -55.2% to -31.5%.
What is the long-term trend for Sana Biotechnology's earnings yield?
Over 4 years (2021 to 2025), Sana Biotechnology's earnings yield has grown at a 16.2% compound annual growth rate (CAGR), from -12.4% to -22.5%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.